Management of type IIb dyslipidemia

Journal of Atherosclerosis and Thrombosis

Volumn 19, Issue 2, 2012, Pages 105-114

  Arai, Hidenori ^a   Ishibashi, Shun ^b   Bujo, Hideaki ^c   Hayashi, Toshio ^d   Yokoyama, Shinji ^e   Oikawa, Shinichi ^f   Kobayashi, Junji ^g   Shirai, Kohji ^h   Ota, Takao ⁱ   Yamashita, Shizuya ^j   Gotoda, Takanari ^k   Harada Shiba, Mariko ^l   Sone, Hirohito ^m   Eto, Masaaki ⁿ   Suzuki, Hiroaki ^m   Yamada, Nobuhiro ^m  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^f NIPPON MEDICAL SCHOOL   (Japan)

^g KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^h Sakura Hospital   (Japan)

ⁱ UNIVERSITY OF THE RYUKYUS   (Japan)

^j OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^l NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^m UNIVERSITY OF TSUKUBA   (Japan)

ⁿ OHU UNIVERSITY   (Japan)

more..

Author keywords

Atherogenic dyslipidemia; Cardiovascular disease; Diabetes; Lifestyle modification; Metabolic syndrome

Indexed keywords

APOLIPOPROTEIN A5; APOLIPOPROTEIN B; ATORVASTATIN; BEZAFIBRATE; CREATINE KINASE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PITAVASTATIN; PRAVASTATIN; PROBUCOL; RETINOID X RECEPTOR GAMMA; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UPSTREAM STIMULATORY FACTOR 1; VERY LOW DENSITY LIPOPROTEIN;

ADD ON THERAPY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BODY WEIGHT; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FAMILIAL COMBINED HYPERLIPIDEMIA; FAMILIAL HYPERLIPEMIA; GLUCOSE INTOLERANCE; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; JAPANESE; LIFESTYLE MODIFICATION; LIVER TOXICITY; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; TYPE 2A DYSLIPIDEMIA; TYPE 2B DYSLIPIDEMIA; TYPE 4 DYSLIPIDEMIA;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; DYSLIPIDEMIAS; HUMANS; METABOLIC SYNDROME X;

EID: 84863401674     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.10447     Document Type: Article

References (62)

1. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M: Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb, 2007; 14: 155-158.
2. Krauss RM: Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care, 2004; 27: 1496-1504.
3. Vaziri ND: Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol, 2006; 290: F262-F272.
4. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M: Metabolic syndrome. J Atheroscler Thromb, 2008; 15: 1-5.
5. Gaddi A, Cicero AF, Odoo FO, Poli AA, Paoletti R: Prac-tical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vasc Health Risk Manag, 2007; 3: 877-886.
6. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M: Executive summary of Japan Ath-erosclerosis Society (JAS) guideline for diagnosis and pre-vention of atherosclerotic cardiovascular diseases for Japa-nese. J Atheroscler Thromb, 2007; 14: 45-50.
7. Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T, Shimamoto T, Iida M, Komachi Y: Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol, 2001; 153: 490-499.
8. Satoh H, Nishino T, Tomita K, Tsutsui H: Fasting triglyceride is a significant risk factor for coronary artery disease in middle-aged Japanese men. Circ J, 2006; 70: 227-231
9. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F: Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circula-tion, 1998; 97: 1029-1036.
10. Assmann G, Schulte H, von Eckardstein A: Hypertriglyc-eridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Car-diol, 1996; 77: 1179-1184.
11. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA, 2007; 298: 299-308.
12. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG: Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA, 2008; 300: 2142-2152.
13. Hayakawa T, Okamura T, Okayama A, Kanda H, Watanabe M, Kita Y, Miura K, Ueshima H: Relationship between 5-year decline in instrumental activity of daily living and accumulation of cardiovascular risk factors: NIPPON DATA90. Journal of Atherosclerosis and Thrombosis, 2010; 17: 64-72.
14. Arai H, Yamamoto A, Matsuzawa Y, Saito Y, Yamada N, Oikawa S, Mabuchi H, Teramoto T, Sasaki J, Nakaya N, Itakura H, Ishikawa Y, Ouchi Y, Horibe H, Kita T: Serum lipid survey and its recent trend in the general Japanese population in 2000. J Atheroscler Thromb, 2005; 12: 98-106.
15. Ninomiya T, Kiyohara Y, Kubo M, Yonemoto K, Tanizaki Y, Doi Y, Hirakata H, Iida M: Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. American journal of kidney diseases: the official journal of the National Kidney Foundation, 2006; 48: 383-391.
16. Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, Silberman SR, Wilson PW, Salem DN, Schaefer EJ: Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation, 1992; 85: 2025-2033.
17. Iwata F, Okada T, Kuromori Y, Hara M, Harada K: Screening for familial combined hyperlipidemia in children using lipid phenotypes. J Atheroscler Thromb, 2003; 10: 299-303.
18. Rizzo M, Berneis K: Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention? J Atheroscler Thromb, 2005; 12: 237-239.
19. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG: Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyper-lipidemia. J Clin Invest, 1973; 52: 1544-1568.
20. Wierzbicki AS, Graham CA, Young IS, Nicholls DP: Familial combined hyperlipidaemia: under -defined and under -diagnosed? Curr Vasc Pharmacol, 2008; 6: 13-22.
21. Lee JC, Weissglas-Volkov D, Kyttala M, Sinsheimer JS, Jokiaho A, de Bruin TW, Lusis AJ, Brennan ML, van Greevenbroek MM, van der Kallen CJ, Hazen SL, Paju-kanta P: USF1 contributes to high serum lipid levels in Dutch FCHL families and U.S. whites with coronary artery disease. Arterioscler Thromb Vasc Biol, 2007; 27: 2222-2227.
22. van der Vleuten GM, Isaacs A, Zeng WW, ter Avest E, Talmud PJ, Dallinga-Thie GM, van Duijn CM, Stalenhoef AF, de Graaf J: Haplotype analyses of the APOA5 gene in patients with familial combined hyperlipidemia. Biochim Biophys Acta, 2007; 1772: 81-88.
23. Nohara A, Kawashiri MA, Claudel T, Mizuno M, Tsu-chida M, Takata M, Katsuda S, Miwa K, Inazu A, Kuipers F, Kobayashi J, Koizumi J, Yamagishi M, Mabuchi H: High frequency of a retinoid X receptor gamma gene vari-ant in familial combined hyperlipidemia that associates with atherogenic dyslipidemia. Arterioscler Thromb Vasc Biol, 2007; 27: 923-928.
24. Yamazaki K, Bujo H, Taira K, Itou N, Shibasaki M, Taka-hashi K, Saito Y: Increased circulating malondialdehydemodified LDL in the patients with familial combined hyperlipidemia and its relation with the hepatic lipase activity. Atherosclerosis, 2004; 172: 181-187.
25. Bryniarski L, Dragan J, Zabojszcz M, Klecha A, Jankowski P, Krolikowski T, Rajzer M, Dudek D, Kawecka-Jaszcz K: Intracoronary ultrasound-guided angioplasty for coronary chronic total occlusion. Kardiol Pol, 2009; 67: 992-1003.
26. Shimano H, Arai H, Harada-Shiba M, Ueshima H, Ohta T, Yamashita S, Gotoda T, Kiyohara Y, Hayashi T, Kobayashi J, Shimamoto K, Bujo H, Ishibashi S, Shirai K, Oikawa S, Saito Y, Yamada N: Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target. J Atheroscler Thromb, 2008; 15: 116-121.
27. Packard CJ, Saito Y: Non-HDL cholesterol as a measure of atherosclerotic risk. J Atheroscler Thromb, 2004; 11: 6-14.
28. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sul-livan L, Keyes MJ, Pencina MJ, Schoonmaker C, Wilson PW, D'Agostino RB, Vasan RS: Clinical utility of differ-ent lipid measures for prediction of coronary heart disease in men and women. JAMA, 2007; 298: 776-785.
29. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE: Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk fac-tors for cardiovascular disease in women. JAMA, 2005; 294: 326-333.
30. Sacks FM: Dietary fat, the Mediterranean diet, and health: reports from scientific exchanges, 1998 and 2000. Introduction. Am J Med, 2002; 113 Suppl 9B: 1S-4S.
31. Parikh P, McDaniel MC, Ashen MD, Miller JI, Sorrentino M, Chan V, Blumenthal RS, Sperling LS: Diets and cardiovascular disease: an evidence-based assessment. J Am Coll Cardiol, 2005; 45: 1379-1387
32. Schaefer EJ, Gleason JA, Dansinger ML: The effects of low-fat, high-carbohydrate diets on plasma lipoproteins, weight loss, and heart disease risk reduction. Curr Athero-scler Rep, 2005; 7: 421-427.
33. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M: Treatment-therapeutic lifestyle modification. J Atheroscler Thromb, 2008; 15: 109-115.
34. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Preven-tion Study Group. N Engl J Med, 1995; 333: 1301-1307.
35. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J: Influence of low high-density lipo-protein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation, 2001; 104: 3046-3051.
36. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004; 364: 685-696.
37. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, Keech A, Packard C, Simes J, Byington R, Furberg CD: Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation, 2000; 102: 1893-1900.
38. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 partici-pants in 14 randomised trials of statins. Lancet, 2005; 366: 1267-1278.
39. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH: Joint effects of serum triglyceride and LDL cholesterol and HDL choles-terol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circu-lation, 1992; 85: 37-45.
40. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation, 2000; 102: 21-27.
41. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 peo-ple with type 2 diabetes mellitus (the FIELD study): ran-domised controlled trial. Lancet, 2005; 366: 1849-1861.
42. Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesaniemi YA, Gebski VJ, Scott RS, Keech AC: Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia, 2011; 54: 280-290.
43. Clofibrate and niacin in coronary heart disease. JAMA, 1975; 231: 360-381.
44. Davis HR, Veltri EP: Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb, 2007; 14: 99-108.
45. Ansquer JC, Bekaert I, Guy M, Hanefeld M, Simon A: Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study. Am J Cardiovasc Drugs, 2009; 9: 91-101.
46. Ruggenenti P, Cattaneo D, Rota S, Iliev I, Parvanova A, Diadei O, Ene-Iordache B, Ferrari S, Bossi AC, Trevisan R, Belviso A, Remuzzi G: Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. Diabetes Care, 2010; 33: 1954-1956.
47. Masuda D, Nakagawa-Toyama Y, Nakatani K, Inagaki M, Tsubakio-Yamamoto K, Sandoval JC, Ohama T, Nishida M, Ishigami M, Yamashita S: Ezetimibe improves post-prandial hyperlipidaemia in patients with type IIb hyper-lipidaemia. Eur J Clin Invest, 2009; 39: 689-698.
48. Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, Itoh Y, Yoshikawa T, Fukui M, Hasegawa G, Nakamura N, Ohta M, Obayashi H, Okanoue T: Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol, 2011; 46: 101-107.
49. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, Kontopoulos AG: Safety and efficacy of long-term statin-fibrate combi-nations in patients with refractory familial combined hyperlipidemia. Am J Cardiol, 1997; 80: 608-613.
50. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG: Atorvastatin and micronized feno-fibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care, 2002; 25: 1198-1202.
51. Pauciullo P, Borgnino C, Paoletti R, Mariani M, Mancini M: Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis, 2000; 150: 429-436.
52. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP: Effects of combination lipid therapy in type 2 diabe-tes mellitus. N Engl J Med, 2010; 362: 1563-1574.
53. Guyton JR, Capuzzi DM: Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol, 1998; 82: 82U-4U; discussion 5-6U.
54. Jacobson TA, Chin MM, Fromell GJ, Jokubaitis LA, Amorosa LF: Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol, 1994; 74: 149-154.
55. O'Keefe JH Jr, Harris WS, Nelson J, Windsor SL: Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol, 1995; 76: 480-484.
56. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ: Simvastatin and niacin, antioxi-dant vitamins, or the combination for the prevention of coronary disease. N Engl J Med, 2001; 345: 1583-1592.
57. Weber P, Raederstorff D: Triglyceride-lowering effect of omega-3 LC-polyunsaturated fatty acids--a review. Nutr Metab Cardiovasc Dis, 2000; 10: 28-37.
58. Mozaffarian D, Rimm EB: Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA, 2006; 296: 1885-1899.
59. Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, Jordan HS, Lau J: n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary-and secondary-prevention studies: a systematic review. Am J Clin Nutr, 2006; 84: 5-17.
60. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Stu-dio della Sopravvivenza nell'Infarto miocardico. Lancet, 1999; 354: 447-455.
61. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shi-mada K, Shirato K: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint anal-ysis. Lancet, 2007; 369: 1090-1098.
62. Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, Gottwik M, Steinbeck G, del Castillo U, Sack R, Worth H, Katus H, Spitzer W, Sabin G, Senges J: OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation, 2010; 122: 2152-2159.